Julie Royer
Research Subjects
Julie Royer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Amy Moore
RTI International, Waltham, USA
2 shared publications - Barbara Do
RTI International, Research Triangle Park, USA
2 shared publications - Christine Hill
RTI International (Retired), Decatur, USA
2 shared publications - James F. Howard
Department of Neurology, University of North Carolina, Chapel Hill, USA
2 shared publications Jamie Zimmerman
Division of Birth Defects and Infant Disorders National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, USA
2 shared publications- Joyce T. Alese
Division of Birth Defects and Infant Disorders National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, USA
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 186
Correction: A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
- 7 October 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 186
Open AccessCorrection: A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
- 29 September 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 173
A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
Purpose Review literature on the frequency of sleep disorders and receipt of sleep-related healthcare among individuals with muscular dystrophy. Methods Included: Population–Duchenne/Becker (DBMD), congenital (CMD), facioscapulohumeral (FSHD), limb-girdle (LGMD), or myotonic (DM) muscular dystrophy; Outcomes–frequency of sleep evaluations, disorders, or treatments; Language–English; Study type–original research, systematic review. Excluded: Sample Information sources: PubMed and EBSCO, last searched March 7, 2023. Risk of bias assessment : Recruitment source or study inclusion selected for or against sleep symptoms or disorders. Synthesis: Range and weighted average (low risk studies only) of outcome. Results We included 95 studies of sleep evaluations (7), disorders (94) or treatments (13) with a total of 7,964 participants. Studies reported on DM–61, DBMD–20, FSHD–9, CMD–1, LGMD–1, and multiple MD–3. One-half of people with DBMD (51%, 2 studies, 85 individuals) and over 60% of people with DM1 (65%, 2 studies, 327 individuals) had a sleep study. Measured by questionnaire, excessive daytime sleepiness frequency among adults with DM was 39% (DM2, 10, 284) to 65% (any DM, 6, 1195), 9% among controls (5, 199), and 6% to 13% among other MDs. Sleep apnea frequency was 11% (LGMD, 1, 18) to 65% (CMD, 1, 20). Assisted ventilation use was 5%–16% (DM). Conclusions Regular sleep evaluations may improve identification and treatment of sleep disorders and the physical and mental health of individuals with MD. Other Funding–US Centers for Disease Control and Prevention. Not registered.
- 29 September 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 173
A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
Purpose Review literature on the frequency of sleep disorders and receipt of sleep-related healthcare among individuals with muscular dystrophy. Methods Included: Population–Duchenne/Becker (DBMD), congenital (CMD), facioscapulohumeral (FSHD), limb-girdle (LGMD), or myotonic (DM) muscular dystrophy; Outcomes–frequency of sleep evaluations, disorders, or treatments; Language–English; Study type–original research, systematic review. Excluded: Sample Information sources: PubMed and EBSCO, last searched March 7, 2023. Risk of bias assessment : Recruitment source or study inclusion selected for or against sleep symptoms or disorders. Synthesis: Range and weighted average (low risk studies only) of outcome. Results We included 95 studies of sleep evaluations (7), disorders (94) or treatments (13) with a total of 7,964 participants. Studies reported on DM–61, DBMD–20, FSHD–9, CMD–1, LGMD–1, and multiple MD–3. One-half of people with DBMD (51%, 2 studies, 85 individuals) and over 60% of people with DM1 (65%, 2 studies, 327 individuals) had a sleep study. Measured by questionnaire, excessive daytime sleepiness frequency among adults with DM was 39% (DM2, 10, 284) to 65% (any DM, 6, 1195), 9% among controls (5, 199), and 6% to 13% among other MDs. Sleep apnea frequency was 11% (LGMD, 1, 18) to 65% (CMD, 1, 20). Assisted ventilation use was 5%–16% (DM). Conclusions Regular sleep evaluations may improve identification and treatment of sleep disorders and the physical and mental health of individuals with MD. Other Funding–US Centers for Disease Control and Prevention. Not registered.
- Open Access
- 11 June 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (3) , 67
The New Reality of Infective Endocarditis: Changes in Patient Demographics and Outcomes in South Carolina
Background: Rising rates of opioid use disorder (OUD), usually via injection, has resulted in younger patients being diagnosed with infective endocarditis (IE), with unique treatment challenges. Methods: This retrospective ecological study analyzed hospital discharge and home health records from 2016 to 2022 in South Carolina (SC). Cases of IE with concurrent coding for OUD were identified. Differences in patient demographics, hospital characteristics, length of care days, and charges by OUD status were determined using chi-square or t-tests. IE hospitalization rates by OUD status, year, and age group were calculated, and linear regression was used to determine differences by year. Results: There were 8601 acute-care hospitalization records for IE from 2016 to 2022 in the SC dataset, of which 1180 (13.7%) had concurrent OUD coding. Statistically significant differences between patients with and without OUD were identified for sex, age group, race, resident rurality, average number of comorbidities, disposition status, and year (all p < 0.01). The incidence rate of IE increased from 2.5/100,000 in 2016 to 6.9/100,000 in 2022 in patients aged 36 to 49 years with OUD (p = 0.02). Patients with IE and OUD who were discharged home had significantly longer lengths of stay in acute care hospitals (32.9 vs. 15.3 days; p < 0.01) and excessive hospital charges ($308,874 vs. $188,862) compared to those without OUD. Conclusions: Major changes have occurred in the demographics of IE in SC. The increasing incidence rate of IE in younger adults with OUD coupled with prolonged stays at acute care hospitals pose challenges to the healthcare system that require creative solutions.
- 11 June 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (3) , 67
Open AccessThe New Reality of Infective Endocarditis: Changes in Patient Demographics and Outcomes in South Carolina
Background: Rising rates of opioid use disorder (OUD), usually via injection, has resulted in younger patients being diagnosed with infective endocarditis (IE), with unique treatment challenges. Methods: This retrospective ecological study analyzed hospital discharge and home health records from 2016 to 2022 in South Carolina (SC). Cases of IE with concurrent coding for OUD were identified. Differences in patient demographics, hospital characteristics, length of care days, and charges by OUD status were determined using chi-square or t-tests. IE hospitalization rates by OUD status, year, and age group were calculated, and linear regression was used to determine differences by year. Results: There were 8601 acute-care hospitalization records for IE from 2016 to 2022 in the SC dataset, of which 1180 (13.7%) had concurrent OUD coding. Statistically significant differences between patients with and without OUD were identified for sex, age group, race, resident rurality, average number of comorbidities, disposition status, and year (all p < 0.01). The incidence rate of IE increased from 2.5/100,000 in 2016 to 6.9/100,000 in 2022 in patients aged 36 to 49 years with OUD (p = 0.02). Patients with IE and OUD who were discharged home had significantly longer lengths of stay in acute care hospitals (32.9 vs. 15.3 days; p < 0.01) and excessive hospital charges ($308,874 vs. $188,862) compared to those without OUD. Conclusions: Major changes have occurred in the demographics of IE in SC. The increasing incidence rate of IE in younger adults with OUD coupled with prolonged stays at acute care hospitals pose challenges to the healthcare system that require creative solutions.
- Open Access
- 21 April 2017
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 12 (1) , 1-8
Capture-recapture methodology to study rare conditions using surveillance data for fragile X syndrome and muscular dystrophy
Rare conditions can be catastrophic for families and the implications for public health can be substantial. Our study compared basic surveillance through active medical record review with a linked administrative data file to assess the number of cases of two rare conditions, fragile X syndrome (FXS) and muscular dystrophy (MD) in a population. Two methods of data collection were used to collect information from five counties comprising two standard metropolitan statistical areas of South Carolina. The passive system relied mostly on health claims data using ICD-9 CM diagnostic codes. The active system relied on a nurse abstracting records from a list of all licensed physicians with specialties in neurology, orthopedics, and genetics. There were 141 FXS cases and 348 MD cases that met the case definitions using active surveillance. Additional cases were found for both conditions but they were determined to not be true cases. After linking the actively collected MD and FXS cases to passive datasets, we found that the estimated total numbers of cases were similar to using capture-recapture analysis; the positive predictive values for cases identified in the passive system were 56.6% for MD and 75.7% for FXS. Applying capture-recapture methods to passively collected surveillance data for rare health conditions produced an estimate of the number of true cases that was similar to that obtained through active data collection.
- 21 April 2017
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 12 (1) , 1-8
Open AccessCapture-recapture methodology to study rare conditions using surveillance data for fragile X syndrome and muscular dystrophy
Rare conditions can be catastrophic for families and the implications for public health can be substantial. Our study compared basic surveillance through active medical record review with a linked administrative data file to assess the number of cases of two rare conditions, fragile X syndrome (FXS) and muscular dystrophy (MD) in a population. Two methods of data collection were used to collect information from five counties comprising two standard metropolitan statistical areas of South Carolina. The passive system relied mostly on health claims data using ICD-9 CM diagnostic codes. The active system relied on a nurse abstracting records from a list of all licensed physicians with specialties in neurology, orthopedics, and genetics. There were 141 FXS cases and 348 MD cases that met the case definitions using active surveillance. Additional cases were found for both conditions but they were determined to not be true cases. After linking the actively collected MD and FXS cases to passive datasets, we found that the estimated total numbers of cases were similar to using capture-recapture analysis; the positive predictive values for cases identified in the passive system were 56.6% for MD and 75.7% for FXS. Applying capture-recapture methods to passively collected surveillance data for rare health conditions produced an estimate of the number of true cases that was similar to that obtained through active data collection.